TETRAZOLE functionary is a popular substation for the carboxylic acid group in the drug research field. The drug molecules containing TETRAZOLE group have a long half time in living organism. In addition, four nitrogen atoms of TETRAZOLE offer a greater opportunity in hydrogen bond doner acceptor interactions. In this research work, we described synthesis of new compounds of these families. Using isonicotin aldehyde and hydroxyIamine- hydrochloride in the pyridine, solvent was converted to 4-pyridine carbaldehyde oxime (compound l). Then water absorption process with anhydride acetic. Organize isonicotin nitrile (2). The 4-(2H-TETRAZOLE-5-yl) pyridine (compound 3) was synthesized by [3+2] cyclo addition reaction between compound 2 and NaN3, NH4CI, DMF at 110oC. The structures of all synthesized compounds were investigated by FT-IR and 1 H NMR spectroscopes.

Background: The development of platinum-based metal complexes in oncology is limited due to vigorous toxicity and drug resistance. Objectives: This work aimed to study the cytotoxic activity and apoptosis induction of ruthenium complexes in a B16F10 cell line therapy. Methods: We prepared a series of innovative Ru(II) complexes [Ru(Tzphen)(bpy)(dcbpy)]+2 (S1), [Ru(dcbpy)2(Tzphen)]+2 (S2), [Ru(Phen)2(Tzphen)]+2 (S3), [Ru(Tzphen)(bpy)2]+2 (S4), [Ru(dmbpy)2(Tzphen)]+2 (S5) based on 1,10-phenanthroline ligand containing TETRAZOLE and their anticancer properties investigated by cytotoxicity in vitro, reactive oxygen species, apoptosis with annexin V/PI staining method, autophagy, and cell uptake. Results: S1, S2, S3, S4, and S5 complexes showed comparable cytotoxicity activity relative to cisplatin against the B16F10 model. Moreover, intracellular ROS levels increased due to the presence of the complexes. Among the investigated complexes, the cells treated with the S5 complex indicated the highest apoptotic percentage (Q3) of 14.9% compared to the controls. The cell adsorption of the complexes also showed that the S4 and S5 complexes had higher cell adsorption, better internalization, and higher fluorescence light intensity. Conclusions: The present work provides important guidance for designing and using Ru complexes in cancer therapy.

In this investigation, a combination of Z1-Z5 hydrazone compounds is obtained from the reaction between 4-methylbenzohydrazide and aryl-aldehydes. A subsequent unique synthetic approach to the preparation of di-substituted TETRAZOLEs T6-T10 was achieved through a 1, 3-dipolar cycloaddition of sodium azide and prepared hydrazone compounds in ethyl alcohol. Results have been verified by Fourier-Transform InfraRed (FT-IR)spectroscopy, 1H and 13C-Nuclear Magnetic Resonance (NMR) spectroscopy, and mass spectrometry. The activity of anti-microbial screening has shown that (Z1–, Z6 and T10) presented antifungal activity. The other tested Z2 compound was found to exhibit good antibacterial activity, while the other tested compounds revealed low antibacterial activity.

This study focused on the synthesis of a variety of Schiff bases and their corresponding TETRAZOLE derivatives. The Schiff bases were prepared by reacting quinaldic acid hydrazide with different aromatic aldehydes, followed by cyclization with sodium azide to form TETRAZOLEs. The structures of the synthesized compounds were confirmed using spectroscopic techniques including FT-IR, XRD, FESEM, and ¹H and ¹³C-NMR. Thin-layer chromatography (TLC) was utilized to verify the purity of the compounds. The biological properties of the synthesized compounds were investigated against two bacterial species (Staphylococcus epidermidis and Escherichia coli) and a fungal species (Candida albicans). Furthermore, blind molecular docking studies were performed to identify potential binding sites of these compounds within bacterial and fungal receptors. The antioxidant properties of several compounds were also examined, demonstrating antioxidant activity in some of the selected compounds. The results indicated that the synthesized TETRAZOLE derivatives have significant biological and antioxidant activities, making them potential candidates for further pharmaceutical development.